Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin ER Add-on to Tolterodine for Refractory OAB
NCT01824420Phase 4Completed
- Sponsor
- Buddhist Tzu Chi General Hospital
- Start
- Mar 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin in overactive bladder (OAB), sponsored by Buddhist Tzu Chi General Hospital. Started Mar 2013; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01824420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824420.